A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

This Phase 2 trial (called ZAMBONE) is testing a drug called zanzalintinib in people with advanced or metastatic bone sarcomas — including osteosarcoma, Ewing sarcoma, chondrosarcoma, and other rare bone cancers — that cannot be surgically removed and have progressed after prior treatment. **You may be eligible if...** - You are 18 years or older with a confirmed diagnosis of unresectable, locally advanced, or metastatic bone sarcoma - Your cancer falls into one of these types: osteosarcoma, Ewing sarcoma, conventional chondrosarcoma (grades 2–3), or another primary bone sarcoma - Your cancer has progressed or relapsed after at least one prior treatment - Your cancer has shown progression by imaging within 12 weeks of enrollment (specifically for conventional chondrosarcoma) **You may NOT be eligible if...** - Your cancer is still surgically removable - You have not had prior treatment for your bone sarcoma - Your general health or organ function does not meet the study requirements Talk to your doctor to see if this trial is right for you.